Malignant tumors may lead to the development of FV inhibitors, often associated with the presence of antiphospholipid antibodies (aPL) as a part of paraneoplastic syndrome, which may contribute to the development of AiFVD [13,14]. This evidence concerns the gene F5 and cancer.